Abstract-Angiotensin-(1-7) has been suggested to be a novel vasodilating peptide. We investigated the direct vascular effect of angiotensin-(1-7) in human forearm resistant vessels, particularly with regard to the interaction with angiotensin II, in healthy normotensive men by strain-gauge venous occlusion plethysmography with intra-arterial infusions of peptides. Intra-arterial infusion of angiotensin-(1-7) at 0.1 to 2000 pmol/min did not cause vasodilatation but rather reduced forearm blood flow by Ϸ10% at the highest dose. A placebo-controlled study showed that angiotensin-(1-7) at 0.5 to 40 nmol/min caused weak but significant vasoconstriction (Pϭ0.0016 by ANOVA). Angiotensin-(1-7) at 100 pmol/min, but not at 10 pmol/min, significantly shifted the angiotensin II dose-response curve toward the right (meanϮSD of percent changes in forearm blood flow: Ϫ19Ϯ17%, Ϫ33Ϯ22%, Ϫ55Ϯ12%, Ϫ63Ϯ10%, and Ϫ68Ϯ5% at 5, 10, 25, 50, and 100 pmol/min of angiotensin II, respectively, with saline; 5Ϯ13%, 0.9Ϯ18%, Ϫ40Ϯ16%, Ϫ54Ϯ9%, and Ϫ61Ϯ6% with angiotensin-(1-7), Pϭ0.0021 by ANOVA). Angiotensin-(1-7) did not affect the dose-response curve of noradrenaline [3Ϯ12%, 5Ϯ16%, Ϫ20Ϯ22%, Ϫ31Ϯ18%, and Ϫ40Ϯ12% at 25, 50, 100, 300, and 600 pmol/min of noradrenaline, respectively, with saline; Ϫ4Ϯ15%, Ϫ2Ϯ23%, Ϫ29Ϯ22%, Ϫ34Ϯ16%, and Ϫ42Ϯ9% with angiotensin-(